Posts | Comments

Neutropenia Treatment Market Size Worth $18.9 Billion By 2026 – KBV Research

Contact Us
KBV Research
244 Fifth Avenue, Suite 1407 New York, N.Y. 10001
New York City
New York 10001 
United States
Phone:+1 (646) 661-6066
baleshwar@kbvresearch.com

According to a new report Global Neutropenia Treatment Market, published by KBV research, The Global Neutropenia Treatment Market size is expected to reach $18.9 billion by 2026, rising at a market growth of 6.5% CAGR during the forecast period.

The Retail pharmacy segment is anticipated to dominate the global neutropenia market due to an adequate supply of products and easy availability and accessibility of Retail pharmacies. Online pharmacies are projected to generate significant revenues in the global neutropenia treatment market during the forecast period. The revenue produced from the online pharmacies segment would be greatly improved as this distribution channel provides online information on the product and the possibility of home delivery of the medicines. Doctors involved in the treatment of neutropenia are being redeployed for the treatment of COVID-19 patients due to delays in the treatment of patients affected by neutropenia.

The Colony-stimulating factor market dominated the Global Neutropenia Treatment Market by Treatment in 2019. The Antibiotics market is experiencing a CAGR of 4.9% during (2020 – 2026). Additionally, The Antifungals market would showcase highest CAGR of 7.8% during (2020 – 2026).

North America accounted for the highest share of the worldwide demand for the treatment of neutropenia. The neutropenia treatment market has witnessed a significant rise in North America and is expected to dominate the market over the forecast period. This is due to an increase in the incidence of leukemia in the region. Asia-Pacific is projected to witness the fastest growth rate in the market over the forecast period. Asia has a high potential for growth in the neutropenia treatment market owing to cases of leukemia and the number of patients undergoing first-line chemotherapy.

Structural Insights: https://www.kbvresearch.com/neutropenia-treatment-market/

The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Amgen, Inc., Novartis AG, Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., BeyondSpring, Inc., Spectrum Pharmaceuticals, Inc., Kyowa Kirin Co., Ltd. (Kirin Company), Mylan N.V., Cellerant Therapeutics, Inc., and Partner Therapeutics, Inc.
Global Neutropenia Treatment Market Segmentation

By Distribution Channel
• Retail pharmacies
• Hospital pharmacies and
• Online pharmacies

By Treatment
• Colony-stimulating factor
• Antibiotics
• Antifungals and
• Antivirals

By Geography

North America
• US
• Canada
• Mexico
• Rest of North America

Europe
• Germany
• UK
• France
• Russia
• Spain
• Italy
• Rest of Europe

Asia Pacific
• China
• Japan
• India
• South Korea
• Singapore
• Malaysia
• Rest of Asia Pacific

LAMEA
• Brazil
• Argentina
• UAE
• Saudi Arabia
• South Africa
• Nigeria
• Rest of LAMEA

Companies Profiled
• Amgen, Inc.
• Novartis AG
• Pfizer, Inc.
• Teva Pharmaceuticals Industries Ltd.
• BeyondSpring, Inc.
• Spectrum Pharmaceuticals, Inc.
• Kyowa Kirin Co., Ltd. (Kirin Company)
• Mylan N.V.
• Cellerant Therapeutics, Inc.
• Partner Therapeutics, Inc.

Leave a Reply